GlassScriptPhysician profile
Michael S Park
NPI 1013111624
$5,724.82
in general payments reported to CMS, 2019-2025
52 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $152 · 2021: $2,464 · 2022: $648 · 2023: $870 · 2024: $254 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,105 · Travel and Lodging: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.54 |
| Travel and Lodging | $160.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $2,061.54 | 2021 | |
| Ge Healthcare | $397.60 | 2023-2025 | |
| Zimvie INC. | $232.02 | 2022-2024 | |
| Arthrex, INC. | $209.95 | 2025 | |
| Orthofix Medical, INC. | $187.27 | 2021-2025 | Spinal-Stim |
| Medtronic, INC. | $176.19 | 2023-2025 | Stealthstation S8 Platform, O-Arm, Mazor X System |
| Ucb, INC. | $164.23 | 2019-2023 | Nayzilam, Briviact |
| Coastal Medical Technologies LLC | $162.91 | 2025 | |
| Cvrx, INC. | $150.77 | 2025 | Barostim Neo System |
| Abbott Laboratories | $119.06 | 2023 | Proclaim |
| Sk Life Science, INC. | $119.04 | 2021-2023 | Xcopri |
| Avanir Pharmaceuticals, INC. | $98.04 | 2022 | |
| Abbvie INC. | $92.64 | 2022-2023 | |
| Amgen INC. | $88.51 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $87.24 | 2020-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.